Pain Therapeutics, Inc. (PTIE) Stock Is At All-Time on Jun, 29

June 29, 2018 - By Tyler Harlow

On Jun, 29, all time low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s share price was $2.14. It’s 6.00 % below our $2.01. Barchart.com announced this technical setup. The company has $14.76M market cap. At $2.01 stock price target, the company valuation changes by $885,360 less.

Ticker’s shares touched $2.14 during the last trading session after 5.10% change.Pain Therapeutics, Inc. has 274,326 shares volume, 132.03% up from normal. PTIE is uptrending and has moved 133.72% since June 29, 2017. PTIE outperformed the S&P 500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news announced recently go to: Nasdaq.com, Benzinga.com, Benzinga.com, Marketwatch.com or Seekingalpha.com. The titles are as follows: “Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER” announced on June 26, 2018, “20 Stocks Moving In Thursday’s Pre-Market Session” on June 28, 2018, “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” with a publish date: June 28, 2018, “Pain Therapeutics’ stock plummets 70% after FDA advisory panel vote disappoints” and the last “Key events next week – healthcare” with publication date: June 21, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is valued at $14.76 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.